Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: Pharmacy

  • Joint Commission revises medication safety goals

    The Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL, has announced its 2006 National Patient Safety Goals and related requirements. Several of the revisions to last years goals involve medication safety.
  • Some computerized physician order entry systems are limited, study shows

    Researchers examining adverse drug events (ADEs) at a Veterans Affairs (VA) Hospital in Salt Lake City found surprising results. The computerized physician order entry (CPOE) system had reduced ADEs in some areas, but the rates were higher than expected in decision support.
  • New FDA Approvals

    Entecavir (Baraclude) by Bristol-Myers Squibb Co. The FDA has announced the approval of entecavir (Baraclude) tablets and oral solution for the treatment of chronic hepatitis B in adults. Entecavir slows the progression of chronic hepatitis B virus (HBV) by interfering with viral reproduction.
  • Drug Criteria & Outcomes: Poractant alfa (Curosurf) Formulary Evaluation

    Respiratory Distress Syndrome (RDS), also known as hyaline membrane disease, is one of the leading causes of infant mortality in the United States. The incidence of RDS is approximately 1% of live births.
  • Take a closer look when assessing renal function

    Two men are admitted to the hospital. One is a bodybuilder and looks like Arnold Schwarzenegger. The other is obese and describes himself as a couch potato. They have the same body weight. What is the best way to predict their creatinine clearance?
  • In the Pipeline

    Millennium Pharmaceuticals has initiated EVEREST (Evaluation of Velcade [bortezomib] Employed as Retreatment for Efficacy, Safety, and Tolerability). This is a multicenter Phase IV clinical trial of bortezomib in multiple myeloma patients who have previously responded to bortezomib and relapsed following a treatment-free remission.
  • News Briefs

    Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.
  • Research News: Investigators release data on unexpected ADRs

    In 1998, a multidisciplinary team of investigators initiated RADAR (Research on Adverse Drug events And Reports), a clinically based postmarketing surveillance program that is funded independently of the pharmaceutical industry. RADAR systematically investigates and disseminates information describing serious and previously unrecognized adverse drug and device reactions (ADRs).
  • Get a jump-start on improving your informatics

    If you look at the ability for integrated information systems to allow the power that can be brought on by both information technology and automation to make people more efficient and effective, pharmacists like every other health care provider are struggling to bring their practice into fully supported digital workflow and workload, says Bill G. Felkey, MS, professor of pharmacy care systems at Auburn (AL) University.
  • How safe is your pharmacy? Be on the lookout

    The Joint Commission on Accreditation of Healthcare Organizations recently sent out an alarm about three instances in which impostors posing as surveyors tried to gain access to different hospitals. The impostors left the hospitals when questioned or pressed for identification.